Medical testing equipment maker Hologic said it will acquire competitor Cytyc in a cash-and-stock deal worth $6.2 billion, Hologic announced on Sunday afternoon.
Under terms of the agreement, Cytyc shareholders will receive $16.50 in cash and 0.52 shares of Hologic stock for every share they own.
Cytyc's payout is a 33% premium to its closing price of $35.05 on Friday. The cash portion of the deal will be funded by Goldman Sachs, Hologic said.
"Both Hologic and Cytyc provide some of the most advanced technology addressing women's health needs," said Hologic CEO Jack Cumming," in a prepared statement. "By combining our companies' complementary, best-in-class products and technologies, we expect to drive enhanced growth and value creation."
Cumming will serve as the new company's chief executive and Cytyc CEO Patrick Sullivan will stay on as chairman.
The company said the acquisition, expected to close in the third quarter, will add 10 cents to Hologic's bottom line in the first year.
In 2006, Hologic posted earnings of 56 cents a share on sales of $463 million but prior to the merger announcement Wall Street analysts expect earnings to triple in 2007 on sales growth of 56%, according to Thomson Financial.
Cytyc reported earnings of $1.14 a share on sales of $608 million.